Multiple Sclerosis (MS)
Treatment of patients with relapsing forms of MS (e.g., relapsing-remitting MS [RRMS]).         
Glatiramer acetate is one of several disease-modifying therapies used in the management of RRMS.  Although not curative, these therapies have all been shown to modify several measures of disease activity, including relapse rates, new or enhancing magnetic resonance imaging (MRI) lesions, and disability progression. 
The American Academy of Neurology (AAN) recommends that disease-modifying therapy be offered to patients with RRMS who have had recent relapses and/or MRI activity. Clinicians should consider adverse effects, tolerability, method of administration, safety, efficacy, and cost of the drugs in addition to patient preferences when selecting an appropriate therapy. 
Clinical experience suggests that efficacy of glatiramer acetate is generally similar to that of interferon beta.   Efficacy of glatiramer acetate compared with other disease-modifying therapies (e.g., fingolimod, mitoxantrone, natalizumab) not fully evaluated to date.  
